Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021) - (By Drug Class -Endothelin Receptor Antagonists, Prostacyclin & Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA) and By Country (USA, Canada, UK, Germany, Japan, Brazil, South Africa).
The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in the growth of PAH market. Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to supress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.
Among the drug classes, the market is expected to be driven by ERAs. However, growing number of drugs under prostacyclin are expected to witness tremendous growth in the forecast period.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Global Pulmonary Arterial Hypertension Market is forecasted to grow at a CAGR of 4.95% during 2016 – 2021F, on account of rising prevalence of the PAH disease among the population.
North America region remains the major market followed by Europe in the actual period. In the forecast period, APAC region will witness strong growth driven by the countries such as India and China.
According to Azoth Analytics research report, Global Pulmonary Arterial Hypertension Market: Trends, Opportunities and Forecasts (2016-2021), Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over ~4.95% during 2016 - 2021. On the basis of market segment, Global Pulmonary Arterial Hypertension Market has been segmented By Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)
Scope of the Report
The report provides Segmentation by Drug Class
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA) and By Country (USA, Canada, UK, Germany, Japan, Brazil, South Africa).
The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in the growth of PAH market. Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to supress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.
Among the drug classes, the market is expected to be driven by ERAs. However, growing number of drugs under prostacyclin are expected to witness tremendous growth in the forecast period.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Global Pulmonary Arterial Hypertension Market is forecasted to grow at a CAGR of 4.95% during 2016 – 2021F, on account of rising prevalence of the PAH disease among the population.
North America region remains the major market followed by Europe in the actual period. In the forecast period, APAC region will witness strong growth driven by the countries such as India and China.
According to Azoth Analytics research report, Global Pulmonary Arterial Hypertension Market: Trends, Opportunities and Forecasts (2016-2021), Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over ~4.95% during 2016 - 2021. On the basis of market segment, Global Pulmonary Arterial Hypertension Market has been segmented By Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)
Scope of the Report
The report provides Segmentation by Drug Class
- Endothelin receptor antagonists
- Prostacyclin and Prostacyclin Analogs
- Phosphodiesterase V Inhibitors
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
- USA
- Canada
- UK
- Germany
- Japan
- Brazil
- South Africa
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
3.1. PAH Market to Grow at a Moderate Rate
3.2. ERA to the Drive the PAH Market
3.3. PAH Market to be Dominated by North America and Europe
4. GLOBAL PAH MARKET: AN OVERVIEW
4.1. Product Overview
4.1.1. Global PAH Market, By Value 2011-2015
4.1.2. Global PAH Market, By Value 2016-2021F
4.1.3 Global PAH Market: By Drug Class Type, By Value (2016E-2021F)
Global PAH Market: By Type (Endothelin receptor antagonists, Prostacyclin and Prostacyclin Analogs, Phosphodiesterase V Inhibitors and others)
4.2. Global Endothelin Receptor Antagonist Market
4.2.1. By Value (Historic 2011-15)
4.2.2. By Value (Forecast 2016E-2021F)
4.3. Global Prostacyclin and Prostacyclin Analogs Market
4.3.1. By Value (Historic 2011-15)
4.3.2. By Value (Forecast 2016E-2021F)
4.4. Global Phosphodiesterase V Inhibitors Market
4.4.1. By Value (Historic 2011-15)
4.4.2. By Value (Forecast 2016E-2021F)
4.5. Global Other Drugs Market
4.5.1. By Value (Historic 2011-15)
4.5.2. By Value (Forecast 2016E-2021F)
4.6. PAH Drugs Pipeline Analysis
5. NORTH AMERICA PAH MARKET: AN OVERVIEW
5.1. North America PAH Market
5.1.1. By Value (Historic 2011-15)
5.1.2. By Value (Forecast 2016E-2021F)
5.2. North America PAH Country Market – USA, Canada
6. EUROPE PAH MARKET: AN OVERVIEW
6.1. Europe PAH Market
6.1.1. By Value (Historic 2011-15)
6.1.2. By Value (Forecast 2016E-2021F)
6.2. Europe PAH Country Overview – UK, Germany
7. APAC PAH MARKET: AN OVERVIEW
7.1. APAC PAH Market
7.1.1. By Value (Historic 2011-15)
7.1.2. By Value (Forecast 2016E-2021F)
7.2. APAC PAH Country Overview – Japan
8. LATIN AMERICA PAH MARKET: AN OVERVIEW
8.1. Latin America PAH Market
8.1.1. By Value (Historic 2011-15)
8.1.2. By Value (Forecast 2016E-2021F)
8.2. Latin America PAH Country Overview – Brazil
9. MEA PAH MARKET: AN OVERVIEW
9.1. MEA PAH Market
9.1.1. By Value (Historic 2011-15)
9.1.2. By Value (Forecast 2016E-2021F)
9.2. MEA PAH Country Overview – South Africa
10. MARKET DYNAMICS
10.1. Market Trends & Developments
10.2. Drivers
10.3. Challenges
11. POLICY AND REGULATORY LANDSCAPE
12. M&A AND LICENSING ROUTE TO THE PAH MARKET
13. SWOT ANALYSIS
14. PORTER FIVE FORCE MODEL
15. COMPETITIVE MARKET SHARE ANALYSIS
16. COMPETITIVE LANDSCAPE
17. COMPANY PROFILING
17.1. Actelion Pharmaceuticals Ltd.
17.2. United Therapeutics Corporation
17.3. Gilead sciences
17.4. Bayer AG
17.5. SteadyMed Ltd.
17.6. GlaxoSmithKline plc
17.7. Pfizer Inc.
17.8. Reata Pharmaceuticals Inc.
17.9. Arena Pharmaceuticals Inc.
17.10. Merck & Co. Inc
LIST OF FIGURE
Figure 1: Global PAH Market, 2011-2015 (USD Billion)
Figure 2: Types of pulmonary arterial hypertension
Figure 3: PAH Associated With Other Diseases (APAH)
Figure 4: Global PAH Market, 2016E-2021F (USD Billion)
Figure 5: Global PAH Market: By Drug Class Type, By Value, 2016E (In Percentage)
Figure 6: Global PAH Market: By Drug Class Type, By Value, 2021F (In Percentage)
Figure 7: Global PAH Market: By ERA, By Value, 2011-2021F (in USD Billion)
Figure 8: Global PAH Market: By Prostacyclin and Prostacyclin Analogs, By Value, 2011-2021F (in USD Billion)
Figure 9: Global PAH Market: By Phosphodiesterase V Inhibitors, By Value, 2011-2021F (in USD Million)
Figure 10: Global PAH Market: By Others, By Value, 2011-2021F (in USD Million)
Figure 11: North America PAH Market, 2011-2015 (USD Billion)
Figure 12: North America PAH Market, 2016E- 2021F (USD Billion)
Figure 13: USA PAH Market Size, By Value, 2011-2021F (in USD Billion)
Figure 14: Estimated Number of Cases of PAH in USA
Figure 15: Canada PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 16: Estimated Number of Cases of PAH in Canada
Figure 17: Europe PAH Market, 2011-2015 (USD Billion)
Figure 18: Europe PAH Market, 2016E- 2021F (USD Billion)
Figure 19: UK PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 20: Germany PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 21: Estimated Number of Cases of PAH in Germany
Figure 22: APAC PAH Market, 2011-2015 (USD Million)
Figure 23: APAC PAH Market, 2016E - 2021F (USD Million)
Figure 24: Japan PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 25: Estimated Number of Cases of PAH in Japan
Figure 26: Latin America PAH Market, 2011-2015 (USD Million)
Figure 27: Latin America PAH Market, 2016E- 2021F (USD Million)
Figure 28: Brazil PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 29: Estimated Number of Cases of PAH in Brazil
Figure 30: MEA PAH Market, 2011-2015 (USD Million)
Figure 31: MEA PAH Market, 2016E- 2021F (USD Million)
Figure 32: South Africa PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 33: Estimated Number of Cases of PAH in South Africa
Figure 34: Global PAH Landscape – Market Share (2015)
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
3.1. PAH Market to Grow at a Moderate Rate
3.2. ERA to the Drive the PAH Market
3.3. PAH Market to be Dominated by North America and Europe
4. GLOBAL PAH MARKET: AN OVERVIEW
4.1. Product Overview
4.1.1. Global PAH Market, By Value 2011-2015
4.1.2. Global PAH Market, By Value 2016-2021F
4.1.3 Global PAH Market: By Drug Class Type, By Value (2016E-2021F)
Global PAH Market: By Type (Endothelin receptor antagonists, Prostacyclin and Prostacyclin Analogs, Phosphodiesterase V Inhibitors and others)
4.2. Global Endothelin Receptor Antagonist Market
4.2.1. By Value (Historic 2011-15)
4.2.2. By Value (Forecast 2016E-2021F)
4.3. Global Prostacyclin and Prostacyclin Analogs Market
4.3.1. By Value (Historic 2011-15)
4.3.2. By Value (Forecast 2016E-2021F)
4.4. Global Phosphodiesterase V Inhibitors Market
4.4.1. By Value (Historic 2011-15)
4.4.2. By Value (Forecast 2016E-2021F)
4.5. Global Other Drugs Market
4.5.1. By Value (Historic 2011-15)
4.5.2. By Value (Forecast 2016E-2021F)
4.6. PAH Drugs Pipeline Analysis
5. NORTH AMERICA PAH MARKET: AN OVERVIEW
5.1. North America PAH Market
5.1.1. By Value (Historic 2011-15)
5.1.2. By Value (Forecast 2016E-2021F)
5.2. North America PAH Country Market – USA, Canada
6. EUROPE PAH MARKET: AN OVERVIEW
6.1. Europe PAH Market
6.1.1. By Value (Historic 2011-15)
6.1.2. By Value (Forecast 2016E-2021F)
6.2. Europe PAH Country Overview – UK, Germany
7. APAC PAH MARKET: AN OVERVIEW
7.1. APAC PAH Market
7.1.1. By Value (Historic 2011-15)
7.1.2. By Value (Forecast 2016E-2021F)
7.2. APAC PAH Country Overview – Japan
8. LATIN AMERICA PAH MARKET: AN OVERVIEW
8.1. Latin America PAH Market
8.1.1. By Value (Historic 2011-15)
8.1.2. By Value (Forecast 2016E-2021F)
8.2. Latin America PAH Country Overview – Brazil
9. MEA PAH MARKET: AN OVERVIEW
9.1. MEA PAH Market
9.1.1. By Value (Historic 2011-15)
9.1.2. By Value (Forecast 2016E-2021F)
9.2. MEA PAH Country Overview – South Africa
10. MARKET DYNAMICS
10.1. Market Trends & Developments
10.2. Drivers
10.3. Challenges
11. POLICY AND REGULATORY LANDSCAPE
12. M&A AND LICENSING ROUTE TO THE PAH MARKET
13. SWOT ANALYSIS
14. PORTER FIVE FORCE MODEL
15. COMPETITIVE MARKET SHARE ANALYSIS
16. COMPETITIVE LANDSCAPE
17. COMPANY PROFILING
17.1. Actelion Pharmaceuticals Ltd.
17.2. United Therapeutics Corporation
17.3. Gilead sciences
17.4. Bayer AG
17.5. SteadyMed Ltd.
17.6. GlaxoSmithKline plc
17.7. Pfizer Inc.
17.8. Reata Pharmaceuticals Inc.
17.9. Arena Pharmaceuticals Inc.
17.10. Merck & Co. Inc
LIST OF FIGURE
Figure 1: Global PAH Market, 2011-2015 (USD Billion)
Figure 2: Types of pulmonary arterial hypertension
Figure 3: PAH Associated With Other Diseases (APAH)
Figure 4: Global PAH Market, 2016E-2021F (USD Billion)
Figure 5: Global PAH Market: By Drug Class Type, By Value, 2016E (In Percentage)
Figure 6: Global PAH Market: By Drug Class Type, By Value, 2021F (In Percentage)
Figure 7: Global PAH Market: By ERA, By Value, 2011-2021F (in USD Billion)
Figure 8: Global PAH Market: By Prostacyclin and Prostacyclin Analogs, By Value, 2011-2021F (in USD Billion)
Figure 9: Global PAH Market: By Phosphodiesterase V Inhibitors, By Value, 2011-2021F (in USD Million)
Figure 10: Global PAH Market: By Others, By Value, 2011-2021F (in USD Million)
Figure 11: North America PAH Market, 2011-2015 (USD Billion)
Figure 12: North America PAH Market, 2016E- 2021F (USD Billion)
Figure 13: USA PAH Market Size, By Value, 2011-2021F (in USD Billion)
Figure 14: Estimated Number of Cases of PAH in USA
Figure 15: Canada PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 16: Estimated Number of Cases of PAH in Canada
Figure 17: Europe PAH Market, 2011-2015 (USD Billion)
Figure 18: Europe PAH Market, 2016E- 2021F (USD Billion)
Figure 19: UK PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 20: Germany PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 21: Estimated Number of Cases of PAH in Germany
Figure 22: APAC PAH Market, 2011-2015 (USD Million)
Figure 23: APAC PAH Market, 2016E - 2021F (USD Million)
Figure 24: Japan PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 25: Estimated Number of Cases of PAH in Japan
Figure 26: Latin America PAH Market, 2011-2015 (USD Million)
Figure 27: Latin America PAH Market, 2016E- 2021F (USD Million)
Figure 28: Brazil PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 29: Estimated Number of Cases of PAH in Brazil
Figure 30: MEA PAH Market, 2011-2015 (USD Million)
Figure 31: MEA PAH Market, 2016E- 2021F (USD Million)
Figure 32: South Africa PAH Market Size, By Value, 2011-2021F (in USD Million)
Figure 33: Estimated Number of Cases of PAH in South Africa
Figure 34: Global PAH Landscape – Market Share (2015)
LIST OF TABLES
Table 1: Prostacylin – Pipeline Drugs
Table 2: ERA – Pipeline Drugs
Table 3: PDA 5 Inhibitor – Pipeline Drugs
Table 4: PAH – Pipeline Drugs (Phase I & II)
Table 5: PAH – Pipeline Drugs (Phase III)
Table 6: Mergers and Acquisitions in PAH Market
Table 7: Licensing Agreements in PAH Market
Table 8: PAH Competitive Landscape: Product Benchmarking
Table 9: Actelion –Sales: 2013-2015
Table 10: United Therapeutics –Sales: 2013-2015
Table 11: Gilead Sciences –Sales: 2013-2015
Table 12: Pfizer-Revatio –Sales: 2013-2015
Table 1: Prostacylin – Pipeline Drugs
Table 2: ERA – Pipeline Drugs
Table 3: PDA 5 Inhibitor – Pipeline Drugs
Table 4: PAH – Pipeline Drugs (Phase I & II)
Table 5: PAH – Pipeline Drugs (Phase III)
Table 6: Mergers and Acquisitions in PAH Market
Table 7: Licensing Agreements in PAH Market
Table 8: PAH Competitive Landscape: Product Benchmarking
Table 9: Actelion –Sales: 2013-2015
Table 10: United Therapeutics –Sales: 2013-2015
Table 11: Gilead Sciences –Sales: 2013-2015
Table 12: Pfizer-Revatio –Sales: 2013-2015
